MedTechnology

China’s $2-3B AI Healthcare Pilots Launch: Rural Revolution or Data Control Play?

China’s National Health Commission launched pilots March 1-3, 2026, under its CNY 15-20B ($2-3B) AI strategy—rolling out AI…

ByByAnuja Singh Mar 4, 2026

Azitra Spotlights ATR-12 Phase 1b Data at BIO Summit Miami—50% Enrollment Safety Win Signals Microbiome Biotech Fundraising Surge

Published by BioNextAI Media – Azitra, Inc. (NYSE American: AZTR) takes center stage at the BIO Investment & Growth…

ByByAnuja Singh Mar 2, 2026

Is Johnson & Johnson Preparing to Divest DePuy Synthes in a $20 Billion Strategic Pivot Toward Pharmaceuticals?

Will Johnson & Johnson’s Orthopedics Review Reshape the Global MedTech Landscape? Johnson & Johnson is reportedly exploring a…

ByByAnuja Singh Mar 1, 2026

Can Foundation Medicine and Manifold Redefine Precision Oncology Through AI-Driven Genomic Analytics?

Are Foundation Medicine and Manifold Signaling the Next Evolution of AI-Integrated Oncology Intelligence? In a strategic move to…

ByByAnuja Singh Feb 28, 2026
Image Not Found

Is Insilico’s AI Drug Engine “Einstein” Turning China into the Global AI–Pharma Hub?

Insilico Medicine’s AI‑driven drug discovery platform, Pharma.AI “Einstein,” is scaling fast in China, with a major expansion of…

ByByAnuja Singh Mar 4, 2026

Biotech Licensing Soars to $137B in 2025 – China Now Leads the Licensing Race

The global biotech licensing market hit a record $137 billion in 2025, and 2026 is on track to…

ByByAnuja Singh Mar 4, 2026
Scroll to Top